共 50 条
- [21] Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study (vol 130, pg 886, 2024)CANCER, 2024, 130 (17) : 3046 - 3046Nooka, A. K.Rodriguez, C.Mateos, M., V
- [22] Managing infections, hypogammaglobulinemia, and neutropenia during treatment with teclistamab in relapsed/refractory multiple myeloma: nurse-led experience from the MajesTEC-1 studyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S315 - S315Catamero, DonnaBenito, Patricia BlazquezShenoy, SamanthaChastain, KatherineBanerjee, ArnobQi, KeqinSkerget, SheriDoyle, MargaretKruyswijk, Sandy
- [23] Longer-Term Follow-Up of Patients Receiving Prophylactic Tocilizumab for Cytokine Release Syndrome in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple MyelomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S84 - S85Rosinol, LauraGarfall, AlfredBenboubker, LotfiUttervall, KatarinaGroen, Kazvan de Donk, NielsMatous, JeffreyVishwamitra, DeekshaHodin, CarolineStephenson, TaraQi, KeqinZuppa, AthenaChastain, KatherineMateos Manteca, Maria-Victoria
- [24] Efficacy and Safety of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) With High-Risk (HR) Features: a Subgroup Analysis From the Phase 1/2 MajesTEC-1 StudyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S546 - S547Costa, Luciano J.Bahlis, Nizar J.Usmani, Saad Z.van de Donk, Niels W. C. J.Nooka, Ajay K.Perrot, AuroreQi, KeqinHodin, CarolineUhlar, ClarissaZuppa, AthenaChastain, KatherineDoyle, MargaretMaria-Victoria, Mateos
- [25] Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 StudyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (03): : 194 - 202Martin, Thomas G.Moreau, PhilippeUsmani, Saad Z.Garfall, AlfredMateos, Maria -VictoriaSan-Miguel, Jesus F.Oriol, AlbertNooka, Ajay K.Rosinol, LauraChari, AjaiKarlin, LionelKrishnan, AmritaBahlis, NizarPopat, RakeshBesemer, BrittaMartinez-Lopez, JoaquinDelforge, MichelTrancucci, DaniellePei, LixiaKobos, RachelFastenau, JohnGries, Katharine S.van de Donk, Niels W. C. J.
- [26] Updated Results From the Phase 1/2 MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple MyelomaBRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 35 - 36Popat, RakeshUsmani, Saad Z.Garfall, Alfredvan de Donk, NielsNahi, HarethSan-Miguel, Jesus F.Oriol, AlbertNooka, AjayMartin, ThomasRosinol, LauraChari, AjaiKarlin, LionelBenboubker, LotfiMateos, Maria-VictoriaBahlis, NizarMoreau, PhilippeBesemer, BrittaMartinez-Lopez, JoaquinSidana, SurbhiPei, LixiaTrancucci, DanielleVerona, RalucaGirgis, SuzetteOlyslager, YunsiJaffe, MindyUhlar, ClarissaStephenson, TaraVan Rampelbergh, RianBanerjee, ArnobGoldberg, Jenna D.Kobos, RachelKrishnan, Amrita
- [27] Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1BLOOD, 2022, 140Cortes-Selva, DianaCasneuf, TinekeVishwamitra, DeekshaStein, SarahPerova, TatianaSkerget, SheriRamos, Elenavan Steenbergen, LaureDe Maeyer, DriesBoominathan, RengasamyLau, OnsayDavis, CucBanerjee, ArnobStephenson, TaraUhlar, Clarissa M.Kobos, RachelGoldberg, Jenna D.Pei, LixiaTrancucci, DanielleGirgis, SuzetteLin, Shun Xin WangWu, Liviawati S.Moreau, PhilippeUsmani, SaadBahlis, Nizar JacquesVan de Donk, Niels W. C. J.Verona, Raluca
- [28] Teclistamab, a B-cell maturation antigenxCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 studyLANCET, 2021, 398 (10301): : 665 - 674Usmani, Saad Z.Garfall, Alfred L.van de Donk, Niels W. C. J.Nahi, HarethSan-Miguel, Jesus F.Oriol, AlbertRosinol, LauraChari, AjaiBhutani, ManishaKarlin, LionelBenboubker, LotfiPei, LixiaVerona, RalucaGirgis, SuzetteStephenson, TaraElsayed, YusriInfante, JeffreyGoldberg, Jenna D.Banerjee, ArnobMateos, Maria-VictoriaKrishnan, Amrita
- [29] Longer-Term Follow-up of Patients Receiving Prophylactic Tocilizumab for the Reduction of Cytokine Release Syndrome (CRS) in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma (RRMM)CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S549 - S549van de Donk, Niels W. C. J.Garfall, Alfred L.Benboubker, LotfiUttervall, KatarinaGroen, KazRosinol, LauraMatous, Jeffrey V.Vishwamitra, DeekshaHodin, CarolineStephenson, TaraQi, KeqinZuppa, AthenaChastain, KatherineMateos, Maria-Victoria
- [30] Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple MyelomaBLOOD, 2021, 138Moreau, PhilippeUsmani, Saad Z.Garfall, Alfred L.van de Donk, Niels W. C. J.Nahi, HarethSan-Miguel, JesusOriol, AlbertNooka, Ajay K.Martin, ThomasRosino, LauraChari, AjaiKarlin, LionelBenboubker, LotfiMateos, Maria-VictoriaBahlis, Nizar J.Popat, RakeshBesemer, BrittaMartínez-López, JoaquínSidana, SurbhiPei, LixiaTrancucci, DanielleVerona, Raluca I.Girgis, SuzetteOlyslager, YunsiJaffe, MindyUhlar, Clarissa M.Stephenson, TaraVan Rampelbergh, RianBanerjee, ArnobGoldberg, Jenna D.Kobos, RachelKrishnan, Amrita Y.